CMPS (COMPASS Pathways PLC) Future Price to Earnings

Graphic logo of COMPASS Pathways plc (CMPS)

COMPASS Pathways plc (CMPS) is developing cutting-edge psychiatric treatments based on the creation of unique drugs. Management aims to implement new therapeutic standards through engagement with regulatory bodies. The price action on the GURU.Markets platform is currently at 0.00. Its first-mover status in the niche spares the business from price wars, yet significant risks remain while awaiting the FDA verdict.

Market Cap to Projected Earnings: COMPASS Pathways PLC (CMPS) for 07/04/2022 - 11/10/2026

Metric breakdowns and analytics for COMPASS Corp (CMPS)

- current price and projected stock value:
Stock Quotes COMPASS Pathways|CMPS - Fair Value Consensus
- business market valuation indicators:
Market Value COMPASS Pathways PLC|CMPS - Full Business Value
- balance sheet equity data:
Net Assets per Single Share COMPASS Pathways|CMPS - Book Valuation of Business|Market Cap to Net Assets Ratio compasspathways.com|CMPS - Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital COMPASS Pathways plc|CMPS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital COMPASS Pathways plc|CMPS - Aggregate Debt Obligations|Debt to Book Capitalization Ratio COMPASS Pathways PLC|CMPS - Long-Term Debt|Company Short-Term Debts COMPASS Pathways|Quick Liquidity compasspathways.com
- company profitability and valuation multiples indicators:
CMPS - Company Net Income|Expected Profit COMPASS Pathways plc|CMPS - Price to Earnings Ratio|Future Price to Earnings Compass Pathways|CMPS - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple COMPASS Pathways PLC|CMPS - Operating profit EBITDA|Earnings per share for the last twelve months COMPASS Pathways|CMPS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months compasspathways.com|CMPS - Expected net earnings per share growth this year|Expected earnings per share growth for next year COMPASS Pathways plc
Fundamental valuation:CMPS COMPASS Pathways
Brand item of COMPASS Corp

Forward P/E determines the investment payback period based on the company's expected earnings. By analyzing the forward P/E chart of COMPASS Pathways plc (CMPS), an investor assesses the fairness of the current market capitalization. This metric is calculated by dividing the business value by the projected net income. For COMPASS Pathways plc (CMPS), this indicator reflects market expectations regarding the commercialization of psilocybin-based therapy. High FDA barriers and patent protection make such forecasts the fundamental basis of value.

Competitors of COMPASS Pathways plc (CMPS)

Projected Price to Earnings ALKS (Alkermes)|AVDL (Avadel Pharmaceuticals PLC) - Future Price to Earnings Multiple|Future Price to Earnings atai Life Sciences Corp ATAI|GHRS (GH Research Group) - Price to Expected Earnings Ratio|MNMD - Future Price to Earnings|Market Cap to Projected Earnings lbpharma.us LBRX|DRUG (Bright Minds Biosciences Inc.) - Projected Price to Earnings|Projected Price to Earnings Ratio Vanda Pharma (VNDA)|CYBN (Cybin Inc) - Forward P/E Multiple|Projected Price to Earnings Alto Neuroscience Corp (ANRO)|Forward P/E Multiple NRXP|CING (cingulate.com) - Future Price to Earnings Multiple|Future Price to Earnings Silo Pharma, Inc. SILO|China Pharma Holdings Inc. (CPHI) - Projected Price to Earnings Ratio|Clearmind Medicine - Forward P/E Multiple|Psyence Bio (PBM) - Projected Price to Earnings|SciSparc Ltd (SPRC) - Future Price to Earnings|Projected Price to Earnings Ratio seelostherapeutics.com (SEEL)|Future Price to Earnings Virpax Pharmaceuticals Inc.|Projected Price to Earnings Karuna Therapeutics Inc (KRTX)